Mesoblast Limited
MESO · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.44 | 0.86 | 0.32 | 0.18 |
| FCF Yield | -3.85% | -7.29% | -9.71% | -21.78% |
| EV / EBITDA | -17.41 | -12.93 | -11.97 | -4.57 |
| Quality | ||||
| ROIC | -8.48% | -13.71% | -10.84% | -12.98% |
| Gross Margin | 70.17% | -595.87% | -632.20% | -522.58% |
| Cash Conversion Ratio | 0.49 | 0.55 | 0.77 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | 31.86% | -16.70% | 0.20% | -31.78% |
| Free Cash Flow Growth | -3.88% | 23.27% | 3.68% | 39.06% |
| Safety | ||||
| Net Debt / EBITDA | 0.45 | -1.01 | -0.78 | -0.61 |
| Interest Coverage | -2.72 | -4.07 | -3.56 | -4.66 |
| Efficiency | ||||
| Inventory Turnover | 0.23 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 540.63 | 1,232.91 | 206.64 | 24.88 |